Lack of association between ADRB2 (Gln27Glu) variant with susceptibility, severity and salbutamol response in South Indian asthmatics Authors: Srinivas Bandaru, Sudha Bodduluri, Radhika Swami, Rinku Chaudhary, Khushboo Sharma, Arshiya Khan, Someswar Rao Sagurthi, Koteswara Reddy Gujjula, Praveen Kumar Vemuri, Anuraj Nayarisseri Published: 2026 ABSTRACT AbstractADRB2 gene polymorphisms have been widely studied for their role in influencing asthma pathophysiology. Of particular note, the Gln27Glu (+ 79 C > G, rs1042714) polymorphism, which alters the extracellular domain at the N-terminus of β2AR, leads to the expression of an immature protein. While this polymorphism has been studied in various ethnic groups, its relevance in South Indian asthmatics remains unexplored. The present study, hence, evaluates its association with asthma susceptibility, lung function, disease severity, and response to β2 agonists (salbutamol) in the South Indian cohort. A total of 398 clinically diagnosed asthma patients and 456 healthy controls were recruited. Lung function was assessed using spirometry with age- and race-adjusted values, and severity was classified according to GINA guidelines. Bronchodilator response was assessed by spirometry before and 15 min after salbutamol (200 µg) administration, with a response threshold measured at FEV1 reversibility of ≥ 12%. Genotyping was conducted via allele-specific PCR on blood-derived genomic DNA. Statistical methods were applied to test for the significance of the results. In the present study, there was a lack of significant association between Gln27Glu polymorphism with disease susceptibility, lung function, severity, and bronchodilator response. Additionally, the polymorphism showed no association with response phenotypes across severity subsets. In conclusion, Gln27Glu does not appear to be a crucial ADRB2 polymorphism in asthma susceptibility, nor does it hold clinical significance in modulating pathological conditions, suggesting its limited relevance in South Indian asthmatics.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-53042-0.Keywords: Bronchial Asthma, Gln27Glu polymorphism, Disease susceptibility, Severity, Bronchodilator response, Lung functionSubject terms: Diseases, Genetics, Immunology, Medical research, Molecular biology, Molecular medicine Introduction Asthma is a chronic inflammatory airway disorder affecting approximately 339 million people worldwide1,2. A recent large cross-sectional, multicenter study—Global Burden of Disease (GBD, 1990–2019) report—estimates that India alone contributes to 13.09% of the global burden, with 27.9% of disability-adjusted life years (DALYs)3. Over the past decade, large-scale genome-wide studies on asthma, including the SNP Health Association Resource (SHARe) Asthma Resource Project (SHARP) (https://ncpi-data.org/studies/phs000166), have consistently linked genetic polymorphisms to asthma pathogenesis, severity, and treatment response. Of particular importance, SNPs in the ADRB2 gene that encode β2 adrenergic receptor (β2AR), a 413-residue protein, have been shown to modulate lung function and inter-individual variability in bronchodilator responsiveness in asthma and COPD4–10. Resequencing of the ADRB2 gene identified nearly 80 SNPs11, among which three key non-synonymous polymorphisms—Arg16Gly (rs1042713), Gln27Glu (rs1042714), and Thr164Ile (rs1800888) have been prominently reported to modulate asthma pathophysiology across various ethnicities12–18. Furthermore, in vitro functional studies on human airway smooth muscle cells have demonstrated that these SNPs induce phenotypic changes, including receptor sequestration and altered binding affinities to β2 agonists19–21. Of special relevance, the Gln27Glu polymorphism (rs1042714) in the ADRB2 gene, characterized by a Cytosine-to-Guanine (C→G) base substitution that results in a change from glutamine (Gln) to glutamic acid (Glu) at position 27 of the β2AR, has been extensively investigated for its role in asthma pathology. This substitution occurs in the N-terminal extracellular domain, leading to the increased expression of an immature receptor19. A large-scale population study by Maxwell et al. reported the frequency of the Glu/Glu genotype as 24.6% in Caucasians, 18.7% in Blacks, and 9% in Chinese22. Although variant analysis of Gln27Glu polymorphism in asthma has been conducted across various ethnic groups, studies from the Indian subcontinent, particularly in the South Indian population, remain limited. In this view, the present study aims to investigate the association of the Gln27Glu polymorphism with asthma susceptibility, bronchodilator response to β2-agonist (salbutamol), disease severity, and lung function in South Indian asthmatics. Materials and methods Study population A total of 398 clinically diagnosed asthma patients were recruited in in accordance with Global Initiative for Asthma (GINA) guidelines, 2021 (https://ginasthma.org/gina-reports/)23, from the Government General and Chest Hospital and Gandhi Medical College, Hyderabad, India. In accordance with these guidelines, eligible patients were required to have a significant clinical history of asthma for at least 12 months prior to study enrolment. Patients with evidence of respiratory diseases other than bronchial asthma, such as COPD, bronchiectasis, or other significant lung disorders, were excluded from the study. Further, due to the limited cooperation of paediatric population in pulmonary function tests, the study included only adults aged 20 years and older to ensure a reliable assessment of lung function. A total of 456 age-, gender-, and ethnicity-matched healthy individuals served as controls. None of the control subjects had a family history of asthma, a history of life-threatening diseases (cancers, diabetes, or other chronic/acute disorders), major surgeries (e.g., cardiothoracic or vascular procedures) or severe illness (particularly acute respiratory tract infections) within 12 months prior to study entry. The study protocol was approved by the Institutional Ethics committee for Biomedical Research, Institute of Genetics and Hospital for Genetic Diseases, Osmania University and written informed consent was obtained from all participants prior to study enrolment. Epidemiological data, including age, gender, asthma onset age, substance use, residency, and allergy history, were collected through a standardized questionnaire during personal interviews. All procedures were carried adhering to relevant guidelines and regulations, including the Declaration of Helsinki (https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/) and the Indian Council of Medical Research (ICMR) National Ethical Guidelines for Biomedical and Health Research involving Human Participants, 2017 (https://ethics.ncdirindia.org/ICMR_Ethical_Guidelines.aspx). Pulmonary function test Pulmonary function testing was performed on suspected cases using spirometry (Micro-Medical Limited, Viasys Healthcare, Kent, England) following the recommendations of the American Thoracic Society and the European Respiratory Society (ATS/ERS) guidelines, 2019, employing the device manufacturer-recommended NHANES III (Hankinson) reference equations with a built-in Asian ethnicity correction factor (4–6% reduction vs. Caucasian predicted values)24. All pulmonary function parameters (including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), FEV1/FVC ratio, etc.) were assessed and expressed using prediction equations adjusted for age, gender, smoking status, BMI along with race (Asian)25. All measurements employed the same prediction equations across all patients to avoid genotype-dependent bias in lung function assessment. Assessment of bronchodilator response To assess the bronchodilator response, a standardized dose of 200-µg salbutamol (Asthalin, Cipla Ltd., India) was administered via a metered-dose inhaler (MDI) with a spacer. Pulmonary function testing was performed using spirometry before pre-bronchodilator (Pre-BD) and after post-bronchodilator (Post-BD) administration, with post-bronchodilator measurements taken 15 min after inhalation (ATS/ERS guidelines). The percentage reversibility in FEV1 (% FEV1 Reversibility) was quantified using the Knudson equation26 as follows: Bronchodilator responsiveness was defined based on FEV1 reversibility. Patients exhibiting a ≥ 12% FEV1 reversibility were classified as responders to salbutamol treatment, whereas those with a < 12% were classified as non-responders, in accordance with previously used criteria in asthma pharmacogenetic studies16,27–30. Assessment of asthma severity Asthma severity was classified into mild, moderate, and severe subsets based on the degree of airflow impairment and pattern of exacerbations according to the National Asthma Education and Prevention Program (NAEPP) and the Global Initiative for Asthma (GINA, 2021) guidelines31. Genotyping of ADRB2 Gln27Glu polymorphism Genomic DNA was extracted from whole blood samples of patients and healthy subjects using the standard salting-out method32. Genotyping for the base substitution + 79C > G in the ADRB2 gene corresponding to Gln27Glu polymorphism (rs1042714) was performed using allele-specific polymerase chain reaction (AS-PCR). Briefly, two separate reactions were set up for each allele with target DNA and allele-specific primers. Amplification targeted an 184-bp region in exon 1 of the human ADRB2 gene involving a polymorphism. The primers used were as follows: Antisense (Common Forward) 5’ACAATCCACACCATCAGAAT3’; Sense (Reverse—“C” allele specific) 5’GGACCACGACGTCACGCAGC3’; Sense (Reverse—“G” allele specific) 5’GGACCACGACGTCACGCAG3’. The optimized 20 µL amplification reaction mixture comprised 100 ng of genomic DNA, 0.16 µM of each primer, 30 µM of each dNTP, 1.5 mM MgCl2, and 0.5 Units of Taq DNA polymerase in 1× reaction buffer. The PCR amplification was programmed for initial denaturation at 94.00 °C for 5 min, followed by 35 cycles of 94.00 °C for 30 s, 57.60 °C for 30 s, and 72.00 °C for 30 s, with a final extension at 72 °C for 10 min. Amplified products were resolved on 2% agarose gel, stained with intercalating dye (ethidium bromide), and visualized under UV light with a 100-bp DNA ladder, with the HLA gene (550 bp) serving as an internal control. The AS-PCR assay was initially standardized using no-template (negative) controls (NTC) to ensure reagent purity and exclude cross-contamination. For subsequent genotyping involving large samples, assay reliability was ensured by including HLA internal control and genotyping of samples in replicates, which confirmed reproducibility, and specificity of the assay (Fig. 1, and Supplementary Information Figures S1 and S2). Allele-specific PCR amplification of a 184-bp region in exon 1 of the ADRB2 gene for Gln27Glu genotyping. Each subject (S1, S2, S3) is represented by two adjacent lanes corresponding to allele-specific amplification. The presence of an amplified band in the “C” lane alone indicates the CC (Gln/Gln) genotype, while amplification in the “G” lane alone denotes the GG (Glu/Glu) genotype. The presence of bands in both “C” and “G” lanes signifies a heterozygous CG (Gln/Glu) genotype. “L” represents a 100-bp DNA ladder. Statistical analysis Hardy–Weinberg equilibrium for the Gln27Glu genotypes was tested using the chi-square (χ²) test with Yates’ correction. Deviations in allele and genotype frequencies were evaluated using the χ² test and odds ratios (OR) with 95% confidence intervals (CI). Lung function parameters were analyzed using ANOVA and Student’s t test, with Hartley’s F test applied to assess homogeneity of variance. Multiple comparisons were adjusted using Tukey’s post hoc test and Šidák correction. Statistical significance was determined at a two-tailed p-value threshold of 0.05. Genotypic association analyses were conducted using the SNPStats web server (http://bioinfo.iconcologia.net/en/SNPStats_web) and OpenEpi v2.3.1 (https://www.openepi.com/Menu/OE_Menu.htm). Data visualization and scientific graphing were performed using GraphPad Prism version 6 (Dotmatics, https://www.graphpad.com/). Results Demographic characteristics of the study population A total of 456 healthy controls and 398 clinically defined asthmatics were recruited in the present study. Comparative demographic data is presented in Table 1. Given that the study was age- and gender-matched, no significant differences were observed in the mean age or gender distribution between cases and controls. Patients were recruited from city-based hospitals in Hyderabad, including those with rural influx, while controls were selected from the neighbourhoods of Hyderabad and surrounding rural establishments. Given that cumulative smoking exposure exceeding 5–10 pack-years is a well-established risk factor for COPD and a significant modifier of asthma outcomes, only individuals with < 5 pack-years of smoking exposure were included in the present study. This threshold minimizes smoking-related structural lung damage and fixed airflow limitation, thereby preserving asthma-dominant pathophysiology and bronchodilator reversibility. The same smoking exposure criterion was applied to both asthmatics and non-asthmatic controls, resulting in comparable low-level tobacco exposure between groups and no significant differences in smoking prevalence, thus reducing the potential for differential confounding. Inclusion of light smokers enhances real-world generalizability without introducing clinically meaningful smoking-related bias. Furthermore, all predicted lung-function values were automatically adjusted for smoking status by the spirometry system using NHANES III reference equations, ensuring unbiased and internally consistent genotype–lung function comparisons across exposure groups. (Details of smoking exposure values in patients and controls are summarized in the Supplementary Information., Tables S1, S2, and S3). Further, parental consanguinity was assessed, with non-consanguineous parents predominant in both groups. Table 1Demographic data of asthmatics and controls.ControlsN = 456PatientsN = 398χ2,Odds ratio (95% CI)P-valueGender, n (%) Males187 (41.00)185 (46.48)ref Females269 (59.00)213 (53.52)2.372,0.8 (0.61–1.05)0.123Age (years), (Mean ± SD) Males47.04 ± 10.6446.44 ± 11.24Ref Females44.84 ± 08.4642.24 ± 09.850.001,0.95 (0.53–1.71)0.993Inhabitation, n (%) Urban257 (56.36)241 (60.55)Ref Rural199 (43.64)157 (39.45)1.360,0.84 (0.64–1.10)0.242Smoking status, n (%) Smokers84 (18.42)62 (15.58)Ref Non-smokers372 (81.58)336 (84.42)1.02,1.22 (0.85–1.75)0.314Alcohol consumption, n (%) Alcoholics84 (18.42)57 (14.33)Ref Non-alcoholics372 (81.58)34 (85.67)2.31,0.74 (0.51–1.06)0.129Parental consanguinity, n (%) Yes142 (31.14)101 (25.38)Ref No314 (68.86)297 (74.62)3.192,0.75 (0.55–1.01)0.074Suffering years, (Mean ± SD)13.24 ± 15.60 1–20, n (%)–314 (78.89)–– 21–40, n (%)–51 (12.82)–– ≥ 41, n (%)–33 (8.29)––Family history, n (%) Absent–233 (58.54)–– Present–165 (41.46)––Symptomatic pattern, n (%) Seasonal–294 (73.86)–– Perennial104 (26.14)Allergy induced, n (%) Allergic–380 (95.48)–– Non- Allergic–18 (4.52)–– Demographic data of asthmatics and controls. 2.372, 0.8 (0.61–1.05) 0.001, 0.95 (0.53–1.71) 1.360, 0.84 (0.64–1.10) 1.02, 1.22 (0.85–1.75) 2.31, 0.74 (0.51–1.06) 3.192, 0.75 (0.55–1.01) Asthmatics had a mean disease duration of 13.24 years with the majority of patients experiencing symptoms for 1–20 years. Familial predisposition (maternal and/or paternal history of asthma) was observed in 41.45% of patients. Further, a higher proportion of patients showed allergy-induced exacerbations and seasonal variations (worsening symptoms during winter or humid conditions). Analysis of pulmonary function in asthmatics According to the Global Initiative for Asthma (GINA) guidelines, patients with a pre-bronchodilator FEV1/FVC ratio of 50–60% were classified as clinical asthmatics in this study, with a mean ratio among recruited asthmatics being 56.64%. The mean FEV1 before bronchodilator administration (FEV1 pre-BD) was 65.55%, which improved significantly to 76.45% following inhalation of 200 µg salbutamol (FEV1 post-BD) (p < 0.01), indicating the overall presence of reversible airflow limitation in the present asthmatic cohort. Pulmonary function assessments are summarized in Table 2. (Further, comparison of lung function parameters stratified by gender are presented in Supplementary Information, Table S4). Table 2Lung function values in general asthmatic population, response phenotypes and severity subsets.Lung function parameters (%-Predicted)FEV1FVCFEV1/FVCFEV1 Reversibility (%)Pre-BD (Mean ± SD)Post-BD (Mean ± SD)P-valuePre-BD (Mean ± SD)Post-BD (Mean ± SD)P-valuePre-BD (Mean ± SD)Post-BD (Mean ± SD)P-valueAll asthmatics (N = 398)65.55 ± 21.8576.45 ± 26.90< 0.00167.30 ± 23.4878.10 ± 23.060.17356.64 ± 1.9856.88 ± 1.81< 0.00116.05 ± 6.67Response phenotypes Responders (N = 261)68.88 ± 22.7683.04 ± 27.60< 0.00169.20 ± 29.8681.10 ± 40.740.62856.66 ± 2.0859.15 ± 1.4070.02120.49 ± 3.56 Non-Responders (N = 137)59.21 ± 18.4661.86 ± 20.280.28561.30 ± 22.3267.61 ± 32.820.88956.62 ± 1.77653.69 ± 2.0820.7847.69 ± 1.60 P-valuea< 0.001< 0.001< 0.001< 0.0010.9960.031< 0.001Severity subsets Mild (N = 102)83.43 ± 7.4294.71 ± 12.65< 0.00186.10 ± 15.5493.00 ± 16.29< 0.00156.49 ± 1.9159.08 ± 2.670.10117.36 ± 6.39 Moderate (N = 127)67.37 ± 4.3578.77 ± 7.210.01668.50 ± 8.5777.30 ± 6.840.05256.86 ± 1.9359.17 ± 1.110.39816.86 ± 6.53 Severe (N = 169)44.95 ± 5.8651.60 ± 7.790.03146.08 ± 9.0056.36 ± 9.010.10456.58 ± 2.0758.10 ± 1.610.59114.65 ± 6.70 P-valuea< 0.001< 0.001< 0.001< 0.0010.32< 0.0010.001aP-value for Comparison of lung function between the given groups (either response phenotypes or severity subsets). Lung function values in general asthmatic population, response phenotypes and severity subsets. aP-value for Comparison of lung function between the given groups (either response phenotypes or severity subsets). Identifying responding and non-responding phenotypes for salbutamol Among the 398 asthmatic patients in the present study, 261 (65.58%) were classified as responders, while 137 (34.42%) were non-responders to bronchodilator inhalation (salbutamol, 200 µg). As shown in Table 2, responders exhibited a significant post-bronchodilator improvement in FEV1 (p < 0.001), whereas non-responders showed a negligible increase (p = 0.285). However, rather than assessing response based on FEV1 endpoint, a significant bronchodilator response was defined as FEV1 reversibility of > 12%, based on the Knudson equation26. Responders demonstrated significantly greater reversibility (20.49 ± 3.56) than non-responders (7.69 ± 1.60, p < 0.001), reflecting substantial improvement in lung function following salbutamol administration. In contrast, non-responders exhibited minimal change, indicating notable refractoriness to salbutamol treatment. The epidemiological characteristics of the response phenotypes are presented in Supplementary Table S5, while comparisons of lung function parameters between male and female patients stratified by response phenotype are provided in Supplementary Table S6. Determination of asthma severity In the present study, among 398 asthma subjects, 102 (25.63%), 127 (31.91%), and 169 (42.46%) were classified as having mild, moderate, and severe asthma, respectively. The higher proportion of severe asthma cases in the present study can be attributed to the persistence of symptoms despite home treatment, resulting in more frequent hospital visits (where samples were collected from patients). As can be observed from Table 2, pre-bronchodilator (Pre-BD) FEV1 values were highest in the mild group and progressively declined in the moderate and severe groups (p < 0.001). Post-bronchodilator (Post-BD) FEV1 followed a similar trend, remaining lowest in severe asthmatics compared to mild and moderate asthmatics (p < 0.001). Furthermore, other key pulmonary function parameters, including FVC, FEV1/FVC ratio, and FEV1 reversibility, in addition showed a progressive decline with increasing asthma severity. These findings thus clearly align with the GINA classification, which defines asthma severity based on the progressive decline in baseline lung function. The epidemiological characteristics of patients stratified by disease severity are presented in Supplementary Table S7, while the comparison of lung function parameters between male and female patients across severity categories is provided in Supplementary Table S8. Gln27Glu polymorphism and disease susceptibility The genotypic distribution of the Gln27Glu polymorphism in asthmatics and healthy controls is presented in Table 3. No significant association was observed between this polymorphism and asthma susceptibility (Controls vs. Patients: Gln/Gln vs. Glu/Glu, p = 0.463; Gln vs. Glu, p = 0.409). Furthermore, none of the tested inheritance models, and allelic distribution, demonstrated a significant association between the polymorphism and asthma risk. These findings thus indicate that the Gln27Glu polymorphism is unlikely to be a major genetic determinant of asthma susceptibility in the South Indian population. (The distribution of genotypes stratified by gender within the asthmatic patient population is presented in Table S9, while genotype distribution across smoking status among asthmatics is provided in Table S10). Table 3Genotype and allelic distribution for Gln27Glu polymorphism in controls and asthmatics.ModelGenotypeControlsN = 456n (%)PatientsN = 398n (%)Odds ratio(95% CI)χ2P-valueCo dominantGln/Gln193 (42.33)174 (43.72)RefGln/Glu138 (30.26)126 (31.66)1.04 (0.75–1.42)0.0010.998Glu/Glu125 (27.41)98 (24.62)0.87 (0.62–1.21)0.5380.463DominantGln/Gln193 (42.32)174 (43.72)RefGln/Glu-Glu/Glu263 (57.68)224 (56.28)0.95 (0.73–1.25)0.1160.732RecessiveGln/Gln-Gln/Glu331 (72.58)300 (75.37)RefGlu/Glu125 (27.42)98 (24.63)0.86 (0.63–1.16)0.7180.396Over dominantGln/Gln-Glu/Glu318 (69.73)272 (68.34)RefGln/Glu138 (30.24)126 (31.66)1.09 (0.82–1.46)0.1330.714Allele frequenciesGln524 (57.46)474(59.54)RefGlu388(42.54)322(40.45)0.92 (0.75–1.11)0.6810.409Hardy-Weinberg equilibrium (HWE) test χ2 at 2 df; Controls = 12.74; Patients = 24.63. Genotype and allelic distribution for Gln27Glu polymorphism in controls and asthmatics. Hardy-Weinberg equilibrium (HWE) test χ2 at 2 df; Controls = 12.74; Patients = 24.63. Analysis of polymorphism and salbutamol response We next investigated the possible association of the Gln27Glu polymorphism with salbutamol response in patients. We found no significant association between this polymorphism and response phenotypes, indicating that Gln27Glu is not a key determinant of salbutamol refractoriness. As summarized in Table 4, none of the inheritance models demonstrated a significant association between the Gln27Glu polymorphism and salbutamol response (All inheritance models, p > 0.05). These findings suggest that the Gln27Glu polymorphism does not affect the pharmacogenetic variability of salbutamol response, at least in South Indian asthmatics. Table 4Genotype and allelic distribution for Gln27Glu polymorphism in responders and non-responders to salbutamol.ModelGenotypeResponders (N = 261)n (%)Non-Responders (N = 137)n (%)OR (95% CI)χ2P-valueCo dominantGln/Gln111 (42.53)63 (45.99)RefGln/Glu83 (31.80)43 (31.39)0.91 (0.56–1.48)0.0620.802Glu/Glu67 (25.67)31 (22.63)0.82 (0.48–1.38)0.3950.529DominantGln/Gln111 (42.53)63 (45.99)RefGln/Glu-Glu/Glu150 (57.47)74 (54.01)0.87 (0.57–1.32)0.3070.579RecessiveGln/Gln-Gln/Glu194 (74.33)106 (77.37)RefGlu/Glu67 (25.67)31 (22.63)0.85 (0.52–1.38)0.2990.307Over dominantGln/Gln-Glu/Glu178 (68.20)94 (68.61)RefGln/Glu83 (31.80)43 (31.39)0.98 (0.63–1.53)0.0010.976AllelefrequenciesGln305 (58.43)169 (61.68)RefGlu217 (41.57)105 (38.32)0.90 (0.67–1.22)0.3270.567 Genotype and allelic distribution for Gln27Glu polymorphism in responders and non-responders to salbutamol. Allele frequencies Analysis of polymorphism with asthma severity Similar to its lack of association with salbutamol response, the Gln27Glu polymorphism showed no significant association with asthma severity. As shown in Table 5, genotypic distributions did not significantly differ across mild, moderate, and severe asthma groups (p > 0.05). Further, distributions of Gln and Glu alleles across the severity subsets revealed no significant association with disease severity (p > 0.05). Furthermore, the lack of association extends to both dominant and recessive inheritance models as well. These findings hence suggest that the Gln27Glu polymorphism does not significantly modulate asthma severity in the present population. Table 5Genotypes and allelic distribution of Gln27Glu polymorphism in severity subsets.Inheritance modelGenotypeMild N = 102n %Moderate N = 127n %Severe N = 169n %Mild vs. ModerateMild vs. SevereModerate vs. SevereSevere vs. Mild and ModerateCo- dominantGln/Gln47 (46.08)55 (43.31)72 (42.60)RefRefRefRefGln/Glu33 (32.4)39 (30.71)54 (31.95)OR (CI) = 1.01 (0.55–1.85)χ2 = 0.01p = 0.901OR (CI) = 1.07 (0.61–1.88)χ2 = 0.01p = 0.991OR (CI) = 1.06 (0.62–1.82)χ2 = 0.01p = 0.952OR (CI) = 1.063 (0.67–1.69)χ2 = 0.02p = 0.899Glu/Glu22 (21.57)33 (25.98)43 (25.44)OR (CI) = 1.28 (0.65 2.49)χ2 = 0.32p = 0.572OR (CI) = 1.27 (0.68–2.46)χ2 = 0.36p = 0.552OR (CI) = 0.99 (0.56–1.76)χ2 = 0.01p = 0.895OR (CI) = 1.11 (0.67–1.83)χ2 = 0.07p = 0.790DominentGln/Gln47 (46.08)55 (43.31)72 (42.60)RefRefRefRefGln/Glu-Glu/Glu55 (53.92)72 (56.69)97 (57.40)OR (CI) = 1.69 (0.99–2.86)χ2 = 3.28p = 0.074OR (CI) = 1.15 (0.70–1.88)χ2 = 0.19p = 0.664OR (CI) = 1.03 (0.65–1.64)χ2 = 0.00p = 0.993OR (CI) = 1.08 (0.72–1.62)χ2 = 0.01p = 0.782RecessiveGlu/Glu22 (21.57)33 (25.98)43 (25.44)RefRefRefRefGln/Gln-Gln/Glu80 (78.43)94 (74.02)126 (74.56)OR (CI) = 0.66 (0.35–1.23)χ2 = 135p = 0.253OR (CI) = 0.81(0.45–1.49)χ2 = 0.33p = 0.562OR (CI) = 1.03 (0.61–1.74)χ2 = 0.00p = 0.981OR (CI) = 0.93 (0.58–1.47)χ2 = 0.01p = 0.834Allele frequenciesGln127 (62.25)149 (58.66)198 (58.58)RefRefRefRefGlu77 (37.75)105 (41.34)140 (41.42)OR (CI) = 1.16 (0.79–1.69)χ2 = 0.47p = 0.490OR (CI) = 1.17 (0.82–1.66)χ2 = 0.57p = 0.451OR (CI) = 1.00 (0.72–1.39)χ2 = 0.00p = 0.957OR (CI) = 1.07 (0.81–1.43)χ2 = 0.16p = 0.692Mild vs. Moderate vs. Severeχ2P-valuedfGenotypes0.7670.9424Alleles0.8340.6582 Genotypes and allelic distribution of Gln27Glu polymorphism in severity subsets. OR (CI) = 1.01 (0.55–1.85) χ2 = 0.01 p = 0.901 OR (CI) = 1.07 (0.61–1.88) χ2 = 0.01 p = 0.991 OR (CI) = 1.06 (0.62–1.82) χ2 = 0.01 p = 0.952 OR (CI) = 1.063 (0.67–1.69) χ2 = 0.02 p = 0.899 OR (CI) = 1.28 (0.65 2.49) χ2 = 0.32 p = 0.572 OR (CI) = 1.27 (0.68–2.46) χ2 = 0.36 p = 0.552 OR (CI) = 0.99 (0.56–1.76) χ2 = 0.01 p = 0.895 OR (CI) = 1.11 (0.67–1.83) χ2 = 0.07 p = 0.790 OR (CI) = 1.69 (0.99–2.86) χ2 = 3.28 p = 0.074 OR (CI) = 1.15 (0.70–1.88) χ2 = 0.19 p = 0.664 OR (CI) = 1.03 (0.65–1.64) χ2 = 0.00 p = 0.993 OR (CI) = 1.08 (0.72–1.62) χ2 = 0.01 p = 0.782 OR (CI) = 0.66 (0.35–1.23) χ2 = 135 p = 0.253 OR (CI) = 0.81 (0.45–1.49) χ2 = 0.33 p = 0.562 OR (CI) = 1.03 (0.61–1.74) χ2 = 0.00 p = 0.981 OR (CI) = 0.93 (0.58–1.47) χ2 = 0.01 p = 0.834 OR (CI) = 1.16 (0.79–1.69) χ2 = 0.47 p = 0.490 OR (CI) = 1.17 (0.82–1.66) χ2 = 0.57 p = 0.451 OR (CI) = 1.00 (0.72–1.39) χ2 = 0.00 p = 0.957 OR (CI) = 1.07 (0.81–1.43) χ2 = 0.16 p = 0.692 Genotype and allele distribution in response phenotypes stratified into severity subsets Given the lack of a significant association of the Gln27Glu polymorphism with both response phenotypes and asthma severity, we further stratified response phenotypes by severity subsets to explore possible association of the variant within these stratified groups. The analysis revealed that only the Gln/Gln genotype had a significant association with responders in severe asthmatics (p = 0.03; Table 6). However, the Gln/Glu and Glu/Glu genotypes, as well as allelic distribution, showed no significant association with response phenotypes across any severity subset (p > 0.05). Furthermore, while the wild-type Gln/Gln genotype was marginally more prevalent among both responders and non-responders across all severity groups, this distribution was not statistically significant (for all genotype comparisons in respective severity subset p > 0.05). Table 6Genotype allele distribution in response phenotypes stratified into severity subsets.RespondersNon-RespondersOR (95% CI)χ2, P-valueGenotype-wise distribution of severity (N = 398) Gln/Gln(N = 174)N = 111 n (%)N = 63 n (%)Mild (N = 47)35 (20.11)12 (6.90)RefModerate (N = 55)38 (21.84)17 (9.77)1.30 (0.55–3.11)0.14, 0.70Severe (N = 72)38 (21.84)34 (19.54)2.61 (1.17–5.82)4.76, 0.03 Gln/Glu(N = 126)N = 83 n (%)N = 43 n (%)Mild (N = 33)24 (19.05)9 (7.14)RefModerate (N = 39)27 (21.43)12 (9.52)1.19 (0.43–3.30)0.01, 0.95Severe (N = 54)32 (25.4)22 (17.46)1.83 (0.72–4.69)1.09, 0.30 Glu/Glu(N = 98)N = 67 n (%)N = 31 n (%)Mild (N = 22)15 (15.31)7 (7.14)RefModerate (N = 33)25 (25.51)8 (8.16)0.69 (0.21–2.28)0.09, 0.76Severe (N = 43)27 (27.55)16 (16.33)1.27 (0.43–3.78)0.02, 0.88Severity-wise distribution of genotypes (N = 398) Mild (N = 102)N = 74 n (%)N = 28 n (%)Gln/Gln (N = 47)35 (34.31)12 (11.76)RefGln/Glu (N = 33)24 (23.53)9 (8.82)1.09 (0.40-3.00)0.01, 0.93Glu/Glu (N = 22)15 (14.71)7 (6.86)1.36 (0.45–4.14)0.39, 0.78 Moderate(N = 127)N = 90 n (%)N = 37 n (%)Gln/Gln (N = 55)38 (29.92)17 (13.39)RefGln/Glu (N = 39)27 (21.26)12 (9.45)0.99 (0.41–2.42)0.05, 0.83Glu/Glu (N = 33)25 (19.69)8 (6.30)0.72 (0.27–1.91)0.18, 0.67 Severe(N = 169)N = 97 n (%)N = 72 n (%)Gln/Gln (N = 72)38 (22.49)34 (20.12)RefGln/Glu (N = 54)32 (18.93)22 (13.02)0.77 (0.38–1.57)0.30, 0.59Glu/Glu (N = 43)27 (15.98)16 (9.47)0.66 (0.31–1.43)0.73, 0.39 Genotype allele distribution in response phenotypes stratified into severity subsets. Gln/Gln (N = 174) Gln/Glu (N = 126) Glu/Glu (N = 98) Moderate (N = 127) Severe (N = 169) Analysis of polymorphism with lung function Next, we examined the influence of the Gln27Glu polymorphism on lung function in asthmatics across three conditions: the overall asthmatic population, response phenotypes to salbutamol, and severity subsets. This comprehensive analysis allowed us to understand the potential role of the Gln27Glu polymorphism on lung function across various clinical contexts. Analysis of lung function across genotypes in the general asthmatic population revealed no significant baseline differences in pre-BD FEV1 values (p > 0.05) or post-BD FEV1 values (p > 0.05) (Table 7). While bronchodilator administration significantly improved FEV1 within each genotype, there were no significant differences observed in FEV1 values upon comparison across genotypes (for Gln/Gln vs. Gln/Glu or Gln/Glu (p > 0.05)) or across all genotypes collectively (p > 0.05), indicating no genotype-based influence on lung function in the asthmatics. Similarly, key lung function parameters—FVC, the FEV1/FVC ratio, and FEV1 reversibility—remained unaffected by genotype, with no significant variation at baseline or after bronchodilator use (p > 0.05). Although bronchodilator administration significantly improved the FEV1/FVC ratio within each genotype (p < 0.0001), the degree of improvement remained similar across genotypes (p > 0.05). These findings indicate that while bronchodilator administration enhances lung function across all genotypes, there is no evidence of genotype-associated variation in lung function. Therefore, the Gln27Glu polymorphism herein does not appear to influence baseline lung function or bronchodilator responsiveness in the present asthmatic population. Table 7Genotype-wise analysis of lung function inpatients.Lung function parameters(%-Predicted)GenotypePre-BDP- valueaP- valuebPost-BDP- valueaP-valuebP- valuecP-valuedP-valueeFEV1Gln/Gln65.93 ± 22.26Ref0.79576.96 ± 27.62Ref0.863< 0.01Ref0.371Gln/Glu66.04 ± 21.790.62276.73 ± 26.580.883< 0.010.389Glu/Glu64.26 ± 21.340.69475.18 ± 26.250.812< 0.010.087FVCGln/Gln67.11 ± 29.80Ref0.63678.00 ± 40.78Ref0.622< 0.01Ref0.395Gln/Glu65.20 ± 28.410.40679.72 ± 38.990.996< 0.010.797Glu/Glu68.50 ± 15.380.34781.20 ± 36.130.924< 0.010.394FEV1/FVCGln/Gln56.47 ± 1.97Ref0.06758.68 ± 1.84Ref0.738< 0.0001Ref0.893Gln/Glu54.98 ± 1.740.40257.57 ± 1.820.842< 0.00010.426Glu/Glu56.52 ± 2.210.67158.96 ± 2.010.816< 0.00010.398FEV1 reversibility (%)Gln/Gln13.47 ± 5.99Ref0.739Gln/Glu15.48 ± 6.240.816Glu/Glu17.63 ± 5.700.721Comparison of:aPre-BD (OR) Post-BD between genotypes considering Gln/Gln genotype as reference.bPre-BD (OR) Post-BD across all genotypes.cPre-BD vs. Post-BD for a given genotype.dPre BD vs. Post BD considering Gln/Gln as reference genotype.ePre BD vs. Post BD across all genotypes.Genotype distribution in patients (N = 398), n (%):Gln/Gln: 174 (43.72%).Gln/Glu: 126 (31.66%).Glu/Glu: 98 (24.62%). Genotype-wise analysis of lung function inpatients. Comparison of: aPre-BD (OR) Post-BD between genotypes considering Gln/Gln genotype as reference. bPre-BD (OR) Post-BD across all genotypes. cPre-BD vs. Post-BD for a given genotype. dPre BD vs. Post BD considering Gln/Gln as reference genotype. ePre BD vs. Post BD across all genotypes. Genotype distribution in patients (N = 398), n (%): Gln/Gln: 174 (43.72%). Gln/Glu: 126 (31.66%). Glu/Glu: 98 (24.62%). On a similar note, none of the genotypes influenced lung function outcomes in either responders or non-responders (Table 8). Instead, lung function improvement was primarily determined by responder status rather than genotype. This observation becomes further evident when responders consistently showed significant improvement in FEV1 after bronchodilator (p < 0.05), while non-responders exhibited minimal changes (p > 0.05), with no significant differences within genotypes (p > 0.05). A similar trend was observed for FVC and the FEV1/FVC ratio, where responders, regardless of genotype, showed significant improvement following bronchodilator administration, whereas non-responders showed no substantial change (p > 0.05). Additionally, FEV1 reversibility, a key endpoint of bronchodilator response, remained consistent across genotypes, with responders demonstrating a reversibility range of 20–22%, compared to 7–9% in non-responders. These findings suggest that lung function improvements are driven by the response phenotype of asthmatics rather than genotype itself, supporting that the Gln27Glu polymorphism does not significantly influence bronchodilator responsiveness. Table 8Lung function analysis in patients stratified by genotype and response phenotype.Lung function parameters(%-Predicted)GenotypeResponsePre-BD Mean ± SDP-valueaP-valuebPost-BD Mean ± SDP-valueaP-valuebP-valuecP-valuedP-valueeFEV1Gln/GlnResponder70.12 ± 23.28RefRef84.76 ± 28.31RefRef< 0.01RefRefNon-Responder58.55 ± 18.290.08163.23 ± 20.15< 0.00010.6170.354Gln/GluResponder69.53 ± 22.84Ref0.49383.44 ± 27.36Ref0.452< 0.01Ref0.211Non-Responder59.70 ± 18.380.11264.24 ± 20.17< 0.010.2990.493Glu/GluResponder66.29 ± 22.12Ref0.26580.00 ± 26.95Ref0.311< 0.05Ref0.572Non-Responder59.87 ± 19.470.08464.77 ± 21.57< 0.050.1020.746FVCGln/GlnResponder65.30 ± 41.78RefRef89.52 ± 42.84RefRef< 0.05RefRefNon-Responder61.60 ± 31.430.05565.90 ± 31.96< 0.010.363< 0.05Gln/GluResponder69.80 ± 39.96Ref0.15483.54 ± 40.63Ref0.662< 0.05Ref0.406Non-Responder66.31 ± 33.880.76269.62 ± 34.200.0720.2210.198Glu/GluResponder67.01 ± 36.14Ref0.54189.91 ± 36.91Ref0.701< 0.05Ref0.106Non-Responder61.02 ± 32.98< 0.0568.20 ± 33.55< 0.050.5430.453FEV1/FVCGln/GlnResponder56.50 ± 2.06RefRef59.21 ± 1.42RefRef< 0.0001RefRefNon-Responder56.42 ± 1.800.10257.75 ± 2.13< 0.00010.3420.662Gln/GluResponder57.05 ± 1.94Ref0.07959.06 ± 1.40Ref0.098< 0.01Ref0.393Non-Responder56.86 ± 1.47< 0.0557.63 ± 2.18< 0.010.1760.535Glu/GluResponder56.44 ± 2.26Ref0.19359.28 ± 1.85Ref0.389< 0.0001Ref0.653Non-Responder56.69 ± 2.09< 0.0557.65 ± 1.91< 0.010.2550.694FEV1Reversibility (%)Gln/GlnResponder20.67 ± 3.31RefRefNon-Responder7.81 ± 1.53< 0.0001Gln/GluResponder20.01 ± 3.06Ref0.817Non-Responder7.42 ± 1.64< 0.0001Glu/GluResponder20.21 ± 3.18Ref0.709Non-Responder7.90 ± 1.78< 0.0001Comparison of: aPre-BD or Post-BD within response phenotypes for a given genotype considering Responder as reference. bPre-BD or Post-BD between genotypes in both responders and non-responders (combined) considering Gln/Gln genotype as reference.cPre-BD vs. Post BD for a given response phenotype and genotype. dPre BD and Post BD (combined) considering responders as reference for a given genotype. ePre-BD and Post BD (combined) for both responders and non-responders (combined) considering Gln/Gln genotype as reference. Genotype distribution in response phenotypes, (N = 398). n (%): Gln/Gln: Responders 111 (42.53), Non-Responders 63 (45.99). Gln/Glu: Responders 83 (31.80), Non-Responders 43 (31.39). Glu/Glu: Responders 67 (25.67), Non-Responders 31 (22.63). Lung function analysis in patients stratified by genotype and response phenotype. Comparison of: aPre-BD or Post-BD within response phenotypes for a given genotype considering Responder as reference. bPre-BD or Post-BD between genotypes in both responders and non-responders (combined) considering Gln/Gln genotype as reference. cPre-BD vs. Post BD for a given response phenotype and genotype. dPre BD and Post BD (combined) considering responders as reference for a given genotype. ePre-BD and Post BD (combined) for both responders and non-responders (combined) considering Gln/Gln genotype as reference. Genotype distribution in response phenotypes, (N = 398). n (%): Gln/Gln: Responders 111 (42.53), Non-Responders 63 (45.99). Gln/Glu: Responders 83 (31.80), Non-Responders 43 (31.39). Glu/Glu: Responders 67 (25.67), Non-Responders 31 (22.63). The study further aimed to determine whether the Gln27Glu polymorphism influences lung function across different asthma severity subsets (mild, moderate, and severe). As demonstrated in Table 9, the analysis reveals a significant decline in lung function parameters, including FEV1, FVC, and FEV1/FVC ratio, with increasing disease severity (p < 0.0001). However, these changes are independent of genotype (p > 0.05; considering comparison of genotypes with Gln/Gln as reference, or collectively across all the genotypes), suggesting that the severity of airflow limitation is driven by disease progression rather than genetic variation. Further, both Pre-BD and Post-BD FEV1 values were significantly lower in moderate and severe asthmatics compared to mild cases across all genotypes (p < 0.0001); however, this decline was not genotype specific. Within each severity subset and irrespective of genotypes, bronchodilator response (Pre-BD vs. Post-BD) remained significant in mild and moderate asthmatics but was only marginally significant in severe cases, likely due to a higher proportion of salbutamol non-responders in this group (Supplementary information, Table S11). Importantly, upon comparing Pre-BD and Post-BD FEV1 (individually or combined) across genotypes (considering Gln/Gln as the reference), no statistically significant differences were observed, further confirming that genotype does not influence lung function outcomes (p > 0.05). A similar trend was observed for FVC function, where values declined with increasing severity across all genotypes (p < 0.0001), but no significant differences were found in Pre-BD and Post-BD values when comparing genotypes within each severity subset (p > 0.05). The FEV1/FVC ratio followed the same pattern, showing a significant reduction in severe cases compared to mild and moderate asthma (p < 0.0001), with no significant genotypic variation.FEV1 reversibility, a key marker of bronchodilator response, also exhibited a decreasing trend with increasing severity, which aligns with the expected pathophysiology of β2 agonist refractory asthma. However, as anticipated, the change in the FEV1 reversibility between the genotypes was not statistically significant, further supporting that bronchodilator response is determined by disease severity rather than genetic polymorphism. These findings overall suggest that the Gln27Glu polymorphism does not represent a genetic predisposition variant for pulmonary function outcomes in asthma severity. Further information on lung function values in severity subsets stratified within response phenotypes is presented in Supplementary information, Table S12. (Supplementary analyses in addition include comparisons of mean lung function parameters stratified by smoking status (Table S13) and multivariate comparisons across genotypes stratified by smoking status and clinical (response and severity) phenotypes (Table S14)). Table 9Lung function analysis in patients stratified by genotype and severity.Lung function parameters (%-Predicted)GenotypeSeverityPre-BD Mean ± SDP-valueaP-ValuebPost-BD Mean ± SDP-valueaP-ValuebP-valuecP-ValuedP-ValueeFEV1Gln/GlnMild82.50 ± 6.94RefRef92.40 ± 12.21RefRef< 0.0001RefRefModerate66.98 ± 4.34< 0.000178.18 ± 7.04< 0.0001< 0.00010.052Severe44.52 ± 6.02< 0.000150.96 ± 7.86< 0.00010.072< 0.05Gln/GluMild86.83 ± 7.81Ref0.40994.30 ± 13.10Ref0.337< 0.0001Ref0.463Moderate66.93 ± 4.57< 0.000178.07 ± 7.74< 0.0001< 0.0001< 0.05Severe45.98 ± 5.33< 0.000149.81 ± 7.58< 0.00010.039*< 0.05Glu/GluMild85.67 ± 8.09Ref0.23393.11 ± 13.17Ref0.216< 0.0001Ref0.252Moderate68.53 ± 4.03< 0.000180.59 ± 6.76< 0.0001< 0.00010.066Severe44.39 ± 6.16< 0.000149.14 ± 7.95< 0.0001< 0.050.065FVCGln/GlnMild84.10 ± 17.16RefRef92.38 ± 18.26RefRef0.223RefRefModerate67.30 ± 7.07< 0.000171.10 ± 7.28< 0.00010.414< 0.01Severe49.71 ± 7.95< 0.000152.78 ± 8.02< 0.00010.478< 0.01Gln/GluMild84.92 ± 12.34Ref0.60794.40 ± 12.13Ref0.4590.484Ref0.636Moderate69.87 ± 6.51< 0.000173.32 ± 6.25< 0.00010.683< 0.01Severe48.47 ± 10.12< 0.000141.42 ± 10.17< 0.00010.705< 0.0001Glu/GluMild86.50 ± 15.50Ref0.41291.20 ± 16.40Ref0.6260.384Ref0.621Moderate69.01 ± 6.68< 0.000171.00 ± 6.52< 0.00010.195< 0.01Severe49.88 ± 9.31< 0.000152.82 ± 9.19< 0.00010.348< 0.01FEV1/FVCGln/GlnMild56.39 ± 2.02RefRef59.57 ± 2.36RefRef< 0.0001RefRefModerate56.58 ± 1.98< 0.0559.03 ± 1.500.193< 0.00010.992Severe56.44 ± 1.94< 0.0557.84 ± 1.38< 0.0001< 0.010.846Gln/GluMild57.22 ± 1.38Ref0.22158.60 ± 2.93Ref0.314< 0.05Ref0.338Moderate57.34 ± 1.47< 0.0559.13 ± 0.97< 0.05< 0.010.941Severe56.57 ± 2.14< 0.0558.15 ± 1.27< 0.05< 0.010.841Glu/GluMild55.59 ± 1.96Ref0.11858.76 ± 2.84Ref0.275< 0.0001Ref0.242Moderate56.75 ± 2.240.05859.13 ± 0.720.060< 0.010.868Severe56.82 ± 2.21< 0.0558.49 ± 2.18< 0.05< 0.010.942FEV1 reversibility (%)Gln/GlnMild17.90 ± 6.53RefRefModerate16.68 ± 6.570.454Severe14.38 ± 6.98< 0.05Gln/GluMild16.58 ± 6.35Ref0.219Moderate16.52 ± 6.640.191Severe14.65 ± 6.57< 0.05Glu/GluMild17.40 ± 6.34Ref0.517Moderate17.56 ± 6.510.332Severe15.11 ± 6.53< 0.05Comparison of: aPre-BD or Post-BD within severity subset for a given genotype considering Mild subtypes as reference. bPre-BD or Post-BD between genotypes in all severity subtypes (Mild, Moderate and severe combined) considering Gln/Gln genotype as reference. cPre-BD vs. Post BD for a given severity subtype and genotype. dPre BD and Post BD (combined) considering Mild subtype as reference for a given genotype. ePre BD and Post BD (combined) for all severity subtypes (Mild, Moderate and severe combined) considering Gln/Gln genotype as reference. Genotype distribution in severity subsets, (N = 398), n (%): Gln/Gln: Mild 47 (46.10), Moderate 55 (43.30), Severe 72 (42.60). Gln/Glu: Mild 33 (32.40), Moderate 39 (30.70), Severe 54 (31.90). Glu/Glu: Mild 22 (21.60), Moderate 33 (26.10), Severe 43 (25.40). Lung function analysis in patients stratified by genotype and severity. Comparison of: aPre-BD or Post-BD within severity subset for a given genotype considering Mild subtypes as reference. bPre-BD or Post-BD between genotypes in all severity subtypes (Mild, Moderate and severe combined) considering Gln/Gln genotype as reference. cPre-BD vs. Post BD for a given severity subtype and genotype. dPre BD and Post BD (combined) considering Mild subtype as reference for a given genotype. ePre BD and Post BD (combined) for all severity subtypes (Mild, Moderate and severe combined) considering Gln/Gln genotype as reference. Genotype distribution in severity subsets, (N = 398), n (%): Gln/Gln: Mild 47 (46.10), Moderate 55 (43.30), Severe 72 (42.60). Gln/Glu: Mild 33 (32.40), Moderate 39 (30.70), Severe 54 (31.90). Glu/Glu: Mild 22 (21.60), Moderate 33 (26.10), Severe 43 (25.40). Discussion Since its cloning by Kobilka et al. in 198733, ADRB2 emerged as a key pharmacogenetic gene encoding β2 adrenergic receptor (β2AR), which serves as a primary target of widely prescribed β2 agonists for asthma treatment. ADRB2 has been extensively sequenced across populations, and over 80 non-synonymous polymorphisms were identified. Among these, only a few non-synonymous SNPs like + 46 A > G (Arg16Gly, rs1042713) and + 79 C > G (Gln27Glu, rs1042714) are well-characterized in asthma, with minor allele frequencies of 40–50%34. While + 46 A > G has been widely studied for its association with asthma susceptibility, severity, and pharmacogenetics across various ethnic groups, including Indian cohorts, the pathological significance of + 79 C > G remains unexplored in Indian asthmatics, particularly among the South Indian population. This study, therefore, aims to evaluate the association of the Gln27Glu polymorphism with asthma susceptibility, disease severity, and pharmacogenetic response to β2-agonists (salbutamol) in this underrepresented population. The significance of the Gln27Glu polymorphism has been well-established through studies demonstrating its role in modulating agonist-stimulated down regulation of β2AR in transfected human airway smooth muscle cells. Notably, Finkelstein et al. in 2009 reported that the polymorphism alters receptor function, leading to β2AR down-regulation and reduced responsiveness to β2 agonists16. Given its impact on airway smooth muscle and agonist-induced receptor activity, Gln27Glu is speculated to have pathological implications in bronchial asthma, particularly in the context of pharmacogenetic variability. Despite the recognized cellular significance of the Gln27Glu polymorphism, there was a lack of significant association of this variant with disease susceptibility in the present South Indian asthmatics. Although findings on the role of Gln27Glu polymorphism have been inconsistent for asthma predisposition, meta-analyses have largely suggested a strong bias towards the absence of a significant association. For instance, our findings align with previous reports, including a comprehensive meta-analysis of 45 case-control studies35, which found no significant association of Gln27Glu polymorphism with asthma susceptibility. In further consensus with our findings, D’Amato et al. demonstrated that the homozygous recessive Glu/Glu genotype did not influence airway hyper responsiveness in Italian asthmatics30. Similarly, investigations in German and American Caucasian populations reported no association between the Gln27Glu polymorphism and airway hyper responsiveness36,37. Beyond the general asthmatic population, studies on pediatric asthma have also reported that Gln27Glu polymorphism is not a susceptibility variant, with children homozygous for the variant showed no increased risk of asthma38,39. In contrast to our findings, some studies have reported a significant association of the polymorphism with asthma susceptibility. For instance, studies in the Serbian population40 and Mexican adults41 have suggested that carriers of the minor allele exhibit an increased risk of developing asthma, including the induction of nocturnal asthma. The inconsistencies observed in various populations ascribing the association of Gln27Glu remain elusive; nevertheless, it is worth noticing that in most of the clinical investigations, Gln27Glu polymorphism has not been associated in isolation, but rather its influence was studied in haplotype pairs. This is evident from the aforementioned studies reported from the Italian population and the German population, and the American Caucasian population as well. Another possible rationale is that ADRB2, which codes for β2AR, is a transmembrane protein activated only upon agonist exposure and does not participate in the inflammatory processes underlying asthma. Given that bronchial asthma is an inflammatory disorder, this perhaps may explain why ADRB2 polymorphisms may influence drug responsiveness but do not significantly contribute to disease susceptibility. We further investigated the association of Gln27Glu polymorphism with β2-agonist (salbutamol, 200 µg) responsiveness; however, no significant association was observed in the present asthmatic cohorts. Pharmacogenetic studies across diverse ethnic groups have yielded conflicting results of ADRB2 polymorphisms influencing drug response. Our findings align with previous investigations in populations, including White, African American, and New Zealander cohorts, which reported no association of Gln/Glu variants with variable β2-agonist responsiveness18,42,43. Furthermore, a study by Bleecker et al. found no evidence linking Gln/Glu polymorphisms to therapeutic outcomes, asthma exacerbations, or key asthma control measures, including lung function14. This lack of association between the Gln27Glu polymorphism and bronchodilator response in the present study, as well as in previous reports, is further supported by the pioneering cell-based investigations by Green et al. which showed that β2AR down-regulation occurred only in the presence of Gly16 and Glu27 variants with Gly16 dominating the down-regulation while Glu27 exerting no significant influence. This suggests that the Gly16 locus predominates over Glu27 in regulating β2AR function. Clinically, a similar pattern has been observed in patients, wherein the Arg16Gly variant exerting a more pronounced influence on post-bronchodilator response compared to the Gln27Glu variant44. In our subsequent investigations, we examined the association between the Gln27Glu polymorphism and asthma severity. As anticipated, no significant association was observed. Various studies have reported inconsistent associations between ADRB2 polymorphisms and asthma severity across different ethnic populations. A meta-analysis by Contopoulos-Ioannidis et al. highlighted that most associations between ADRB2 polymorphisms and asthma-related phenotypes, including severity, were statistically insignificant, primarily due to small sample sizes, with less than 2% of findings replicated across independent studies45. However, in contrast, a study by de Paiva et al. in the Brazilian population reported that the Glu/Glu recessive genotype was associated with an increased risk of severe asthma46. We further examined the potential impact of the Gln27Glu polymorphism on lung function parameters (FEV1, FVC, and FEV1 reversibility). Our findings indicate that the Gln27Glu polymorphism does not significantly influence lung function in the overall asthmatic cohort, nor does it distinguish responders from non-responders or patients with mild, moderate, or severe asthma. The present results align with earlier studies by Salah et al. and Limsuwan et al. conducted on Egyptians and Thai populations, respectively, which reported no significant effect of the Gln27Glu genotype on lung function47,48. The rationale for this given lack of association remains elusive, however, as mentioned above, it may be that the dominant Gly16 allele may have an epistatic effect over the Glu27 allele19. The dominance of the Gly16 allele is further confirmed by the studies of Zhang et al. which reported that the Gln27Glu polymorphism alone does not significantly alter lung function; rather, it is specific β2AR haplotypes that influence lung function and airway responsiveness49. Overall, in our study of South Indian asthmatics, we found no significant association of the Gln27Glu polymorphism with asthma susceptibility, bronchodilator response, disease severity, and lung function. Our findings are consistent with the various population-based studies, which have consistently reported a lack of association of this variant with clinical outcomes of bronchial asthma. These population-based studies appear to contradict earlier cell-based studies (such as those by Green et al.19) which demonstrated receptor down-regulation linked to Gln27Glu polymorphism, a mechanism thought to impair bronchodilator response. However, such impairment is not reflected in clinical settings in population-based studies, which is mainly due to the very heterogeneous nature of asthma, wherein, in an asthmatic lung (as opposed to cultured cells), multiple genetic and environmental factors influence treatment responses. Furthermore, pharmacogenetic associations in populations are often modulated by a host of confounding factors, including treatment regimens, type of β2 agonist (SABAs vs. LABAs), ethnicity, and even sex-specific differences50–53. Together, these factors contribute to inter-individual variability in disease outcomes, thereby posing a significant challenge in establishing direct genotype–phenotype correlations as observed in the present study. Despite the strengths of the present study, certain limitations should be acknowledged. Although the overall case–control sample from a South Indian population was adequate for single-SNP association analyses based on prevalence and power considerations, the sample size was relatively limited for within-patient stratifications, including bronchodilator response and asthma severity, particularly after multivariable adjustment. This may have reduced the power to detect modest genetic effects or higher-order interactions; therefore, the lack of significant associations in these subgroup analyses warrants confirmation in larger, independent cohorts. Second, asthma severity classification also represents a potential methodological limitation. Severity was assessed according to GINA guidelines and supported by pulmonary function testing. However, symptom frequency and exacerbation history were largely obtained through patient self-report during outpatient evaluations, which may introduce recall variability. Nevertheless, severity categorization was additionally corroborated by consultant pulmonologists, likely minimizing substantial misclassification and strengthening the clinical validity of the severity groups used. Third, the spirometry interpretation relied on NHANES III reference equations with “manufacturer-applied” Asian correction factors, reflecting standard clinical practice at the time of data collection (prior to 2022). Although population-specific (South Indian) or race-neutral reference equations would have been preferable, it is important to note that all participants were assessed using the same spirometry device and prediction algorithms. Consequently, the internal lung function measurements are consistent, and relative genotype–phenotype associations within this cohort remain unbiased regardless of the reference equation used. Finally, given this given was a focused candidate gene analysis rather than a genome-wide study, ancestry inference or relatedness filtering was not performed in this candidate gene study. The parental consanguinity was included only as a descriptive variable and was not used for analytical adjustment; therefore, subtle effects of population structure cannot be fully excluded. Conclusion We report the first study in the South Indian population to investigate the association of the Gln27Glu polymorphism with asthma susceptibility, pharmacogenetic response to β2-agonists, disease severity, and lung function. Our findings indicate no significant association between this polymorphism and any of these assessed clinical parameters. Given the heterogeneous nature of asthma, further studies examining the role of β2AR haplotypes and gene-gene interactions may provide additional insights into the genetic factors contributing to asthma pathophysiology in South Indian asthmatics. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements We thank the Medical Superintendent and all the staff from the Government. General and Chest Hospital, Hyderabad, India for their cooperation in the study. Our gratitude to all the patients and controls for volunteering for the study. Author contributions - **SB: ** *Conceptualization, Supervision, Methodology, Formal analysis, Writing – Original Draft Preparation*- **RS, RC, KS, AK: ** *Formal analysis* , *Data curation, and Data Visualization*- **SRS: ** *Co-Investigation* , *Data curation* , *technical review*- **SuB: ** *Resources* , *Formal analysis* , *Data curation*- **KRG: ** *Validation* , *Investigation* , *Writing – Review & Editing*- **PKV: ** *Software, Visualization, Data management*- **AN: ** *Project administration, Conceptualization* , *Supervision*. Funding We do not receive any funding for this study. Data availability Most of the data generated or analyzed during this study are included in this article. We have included additional data in the supplementary material. Moreover, queries can be directed to the corresponding author for any clarifications about the study if needed. Declarations Competing interests The authors declare no competing interests. Ethics approval and consent to participate The study has been approved by the Institutional Ethics Committee for Biomedical Research, Institute of Genetics and Hospital for Genetic Diseases, Osmania University. Dated: 03-12-2011. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement Most of the data generated or analyzed during this study are included in this article. We have included additional data in the supplementary material. Moreover, queries can be directed to the corresponding author for any clarifications about the study if needed.